File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

postgraduate thesis: Modulation of atherosclerosis by probiotic bacteria VSL#3 and LGG in ApoE-/- mice

TitleModulation of atherosclerosis by probiotic bacteria VSL#3 and LGG in ApoE-/- mice
Authors
Issue Date2012
PublisherThe University of Hong Kong (Pokfulam, Hong Kong)
Citation
Chan, Y. [陳怡君]. (2012). Modulation of atherosclerosis by probiotic bacteria VSL#3 and LGG in ApoE-/- mice. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b4961742
AbstractAtherosclerosis is the major cause of cardiovascular diseases, which constitute the top ten leading causes of death worldwide. Atherosclerotic plaque development initiates from the inflamed endothelium under an atherogenic environment – chronic low grade inflammation, hypercholesterolemia, endotoxemia, etc. The principal cause of such inflammation has yet to be defined – with growing evidence that microbial stimulants like lipopolysaccharide (LPS) and peptidoglycan (PGN), which can activate toll-like receptors (TLRs) and nuclear factor-kappaB (NFκB) signaling might be the plausible origins. The gastrointestinal tract is suggested to be the major site for absorption and translocation of such stimulants, where gut microbiota have been associated with systemic inflammation and is essential in generating atherogenic substances. Since probiotics have the potential to induce systemic anti-inflammatory effects and fortify gut barrier to reduce bacterial translocation, evaluation of whether probiotics can help reduce atherogenesis was done by feeding the disease model, ApoE-/- mice with high fat diet alone, with telmisartan (1 or 5 mg/kg/day, positive controls) or with probiotics VSL#3 (2.8 x 1011 CFU/day) and/or Lactobacillus rhamnosus strain GG (LGG) (1x108 CFU/day), or the combination of which for 12 weeks. All treatments reduced lesion size significantly; with some treatments reduced plasma endotoxin, cholesterol and various proinflammatory biomarkers. The gut microbiota assessed with PCR-amplified 16S rRNA gene sequences using 454 pyrosequencing and thereafter correlation studies revealed that at least 20 bacterial families that were significantly altered by high fat diet in apolipoprotein E knockout (ApoE-/-)mice correlated with atherosclerotic plaque size and related biomarkers including cholesterol, adipocyte fatty acidbinding protein (A-FABP), etc. Probiotics showed potential in improving atherogenic environment by immunomodulation and induction or inhibition of growth of bacteria correlated with the atherosclerotic plaque and biomarkers. The atherosclerotic condition was also improved by telmisartan, which correlated with the altered gut microbiota. The newly identified atherosclerosis-related gut bacteria will require further exploration into their properties and mechanisms, which will eventually lead to the potential of developing probiotics for the treatment or prevention of atherosclerosis, and thus may be used as an affordable and non-invasive alternative that brings health benefits worldwide.
DegreeDoctor of Philosophy
SubjectAtherosclerosis
Probiotics - Therapeutic use
Dept/ProgramBiological Sciences
Persistent Identifierhttp://hdl.handle.net/10722/193068

 

DC FieldValueLanguage
dc.contributor.authorChan, Yee-kwan-
dc.contributor.author陳怡君-
dc.date.accessioned2013-12-14T10:12:21Z-
dc.date.available2013-12-14T10:12:21Z-
dc.date.issued2012-
dc.identifier.citationChan, Y. [陳怡君]. (2012). Modulation of atherosclerosis by probiotic bacteria VSL#3 and LGG in ApoE-/- mice. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b4961742-
dc.identifier.urihttp://hdl.handle.net/10722/193068-
dc.description.abstractAtherosclerosis is the major cause of cardiovascular diseases, which constitute the top ten leading causes of death worldwide. Atherosclerotic plaque development initiates from the inflamed endothelium under an atherogenic environment – chronic low grade inflammation, hypercholesterolemia, endotoxemia, etc. The principal cause of such inflammation has yet to be defined – with growing evidence that microbial stimulants like lipopolysaccharide (LPS) and peptidoglycan (PGN), which can activate toll-like receptors (TLRs) and nuclear factor-kappaB (NFκB) signaling might be the plausible origins. The gastrointestinal tract is suggested to be the major site for absorption and translocation of such stimulants, where gut microbiota have been associated with systemic inflammation and is essential in generating atherogenic substances. Since probiotics have the potential to induce systemic anti-inflammatory effects and fortify gut barrier to reduce bacterial translocation, evaluation of whether probiotics can help reduce atherogenesis was done by feeding the disease model, ApoE-/- mice with high fat diet alone, with telmisartan (1 or 5 mg/kg/day, positive controls) or with probiotics VSL#3 (2.8 x 1011 CFU/day) and/or Lactobacillus rhamnosus strain GG (LGG) (1x108 CFU/day), or the combination of which for 12 weeks. All treatments reduced lesion size significantly; with some treatments reduced plasma endotoxin, cholesterol and various proinflammatory biomarkers. The gut microbiota assessed with PCR-amplified 16S rRNA gene sequences using 454 pyrosequencing and thereafter correlation studies revealed that at least 20 bacterial families that were significantly altered by high fat diet in apolipoprotein E knockout (ApoE-/-)mice correlated with atherosclerotic plaque size and related biomarkers including cholesterol, adipocyte fatty acidbinding protein (A-FABP), etc. Probiotics showed potential in improving atherogenic environment by immunomodulation and induction or inhibition of growth of bacteria correlated with the atherosclerotic plaque and biomarkers. The atherosclerotic condition was also improved by telmisartan, which correlated with the altered gut microbiota. The newly identified atherosclerosis-related gut bacteria will require further exploration into their properties and mechanisms, which will eventually lead to the potential of developing probiotics for the treatment or prevention of atherosclerosis, and thus may be used as an affordable and non-invasive alternative that brings health benefits worldwide.-
dc.languageeng-
dc.publisherThe University of Hong Kong (Pokfulam, Hong Kong)-
dc.relation.ispartofHKU Theses Online (HKUTO)-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.rightsThe author retains all proprietary rights, (such as patent rights) and the right to use in future works.-
dc.subject.lcshAtherosclerosis-
dc.subject.lcshProbiotics - Therapeutic use-
dc.titleModulation of atherosclerosis by probiotic bacteria VSL#3 and LGG in ApoE-/- mice-
dc.typePG_Thesis-
dc.identifier.hkulb4961742-
dc.description.thesisnameDoctor of Philosophy-
dc.description.thesislevelDoctoral-
dc.description.thesisdisciplineBiological Sciences-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.5353/th_b4961742-
dc.date.hkucongregation2013-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats